Two invention patent applications of Beijing Amet were authorized by the State Intellectual Property Office

Recently, the Chinese invention patent applications "A Personalized Polymer Stent and its Preparation Method and Use" and "Modified Biodegradable Medical Polymer Device and Its Preparation Method" submitted by Beijing Amet won the national intellectual property rights. Office of Patent Licensing. So far, Beijing Amet has 9 invention patents authorized by China and the United States.

2021

08-26

Beijing Amet's high-pressure balloon dilatation catheter product was successfully approved for launch

This high-pressure balloon dilatation catheter from Beijing Amet is suitable for dilating coronary stenotic lesions or bypass stenotic lesions to improve myocardial blood supply; it is suitable for post-implantation expansion of coronary stents. It has excellent product properties, including: excellent shape retention ability under high pressure; excellent "wing" embracing performance, which is conducive to product retraction and secondary entry into the guide tube; hydrophilic coating for durable lubrication effect , can withstand up to 25 rubs. In addition, the product has complete specifications and models and a wide coverage, which can fully meet different clinical needs.

2021

07-16

The randomized controlled trial of 3D printing fully degradable coronary drug-eluting stent system, an innovative device independently developed by Beijing Amet, successfully completed the enrollment of the first three subjects

Recently, a randomized controlled clinical trial of the innovative medical device "3D printing fully degradable coronary drug-eluting stent system (trade name: AMSorbTM)" independently developed by Beijing Amat Medical Devices Co., Ltd. was conducted in Beijing affiliated to Capital Medical University. Anzhen Hospital successfully completed the enrollment of the first three subjects (including two in the experimental group and one in the control group). All three subjects were in good postoperative condition and have been discharged from the hospital.

2021

07-13

Beijing Amet officially obtained the ISO 13485 quality management system certification issued by BSI

Recently, Beijing Amet Medical Devices Co., Ltd. officially obtained the ISO 13485:2016 medical device quality management system certification issued by BSI British Standards Institute. The scope of this certification includes the design and development of Amet's products of a fully degradable peripheral vascular drug-eluting stent system and a high-pressure balloon dilation catheter.

2021

05-14

The project that Beijing Amet participated in the application was approved by the "National Natural Science Foundation of China"

Recently, the National Natural Science and Technology Fund project led by Beijing University of Aeronautics and Astronautics, Beijing Natong Medical and Beijing Amet Medical Equipment Co., Ltd. participated in the joint application was approved. The project will focus on the research on key technical and scientific issues in the optimal design and safety evaluation of bone and cardiovascular absorbable implantable interventional devices.

2021

01-14

Beijing Amet was approved to set up a postdoctoral workstation

Recently, the Ministry of Human Resources and Social Security of the People's Republic of China and the National Postdoctoral Management Committee issued a document that approved the establishment of postdoctoral research stations by 497 units including the Advanced Technology Research Institute of the University of Science and Technology of China. in.

2020

11-28

Our company and the Department of Materials of Fudan University will jointly develop new degradable materials

On November 16, 2020, our company and the Department of Materials of Fudan University signed an agreement to jointly develop a new generation of degradable materials.

2020

11-16

Our company's patent application for vascular stent structure design has been authorized by the State Intellectual Property Office for invention patents

Our company's patent application for the structural design of vascular stent, "A stent with an obturator structure, its preparation method and use", was officially authorized by the State Intellectual Property Office of China on June 30, 2020. Patent number ZL201580079706.4. Our company's 3D printed fully degradable coronary stent, AMSorb®, adopts this structural design and has entered the clinical trial stage. The U.S. patent application for this patent was granted an invention patent by the U.S. Patent Office in March 2020.

2020

07-07

Amet withdrew the application for clinical trial approval of "Fully degradable peripheral vascular drug-eluting stent system", and will resubmit after further improvement of the application materials

Our company's patent application for the structural design of vascular stent, "A stent with an obturator structure, its preparation method and use", was officially authorized by the State Intellectual Property Office of China on June 30, 2020. Patent number ZL201580079706.4. Our company's 3D printed fully degradable coronary stent, AMSorb®, adopts this structural design and has entered the clinical trial stage. The U.S. patent application for this patent was granted an invention patent by the U.S. Patent Office in March 2020.

2020

06-15

Bioresorbable Vascular Scaffold Thrombosis in a Consecutive Cohort of 550 Patients

To determine the rate of bioreasorbable vascular scaffold (BVS) thrombosis in a large, real-world population. BACKGROUND: There is some concern about device thrombosis after percutaneous coronary intervention (PCI) using BVS. No data have been published for PCI using both BVS and metal stents.

2016

08-12

< 12 > proceed page

Company Information

AMT Medical Inc.

Contact Us

ZHEJIANG:  2nd Floor, Building 1, Taizhou Lifa Electronics Co., Ltd., Southeast Corner of Dongdu Middle Road and Zhaozhuang Road, Dayang Street, Linhai City, Taizhou City, Zhejiang Province, China.

 

BEIJING: 26 Yongwang West Road, Building 11, Zhong-guan-cun Medical Device Park, Daxing District, Beijing, China.

 

Tel：+86 -10-6297-7955           E-Mail：amt@ametcorp.com

                                                                sales@ametcorp.com

ewm

WeChat Contact

ewm

Rednote

ewm

TikTok

@Copyright 2022 AMT Medical Inc. All rights reserved

浙ICP备2026047864号   Powered by: www.300.cn   SEO